Boragen said that the $300,500 grant will further accelerate a collaboration with the University of California, San Francisco that focuses on effective control for Plasmodium, the protozoan parasite that causes malaria.

The project will initially leverage Boragen's boron-based small molecular library to identify new targets and modes of action for inhibiting Plasmodium, according to the company. However, the firm said they are also considering a strategy that could both inhibit the parasite and provide the relevant anti-inflammatory effect.